An observational study in Periorbital Hollowing and Skin Aging, sponsored by PharmaResearch Co.,Ltd. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by PharmaResearch Co.,Ltd · Observational
The goal of this clinical study is to learn whether DOT PN (Rejuran S), a polynucleotide injectable gel, improves periorbital hollowing (a sunken look around the eyes) in adults aged 25 to 65 years when injected into the deep layer around the eyes with a blunt cannula. Safety will also be assessed.
The main question it aims to answer is:
- How much do tear trough depth and brow height change from baseline to Week 16, as measured by 3D imaging?
There is no comparison group. All participants receive the study treatment.
Participants will:
PharmaResearch Co.,Ltd is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adults aged 25 to 65 years with periorbital hollowing who are enrolled at 3 study sites in Thailand, Singapore, and Malaysia (approximately 10 participants per site, 30 in total) and who meet the protocol-defined eligibility criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
Exclusion Criteria
An individual who meets any of the following criteria will be excluded from participation in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sterile injectable gel containing 20 mg/mL sodium polynucleotide (1 mL pre-filled syringe). Injected into the periorbital deep (sub-SMAS) plane using a 25G blunt cannula (study-specific technique; the supplied 30G needle is not used), with entry points created by a 23G needle at three sites (ROOF, SOOF, and tear trough), using a linear retrograde and fanning technique. Dose: 2.0 mL per side (4.0 mL per session) at Weeks 0, 4, 8, and 12.
Also known as: Rejuran S, Polynucleotide (PN)
Change From Baseline in Tear Trough Depth at Week 16
Mean change in tear trough depth (mm) from baseline, measured by QuantifiCare 3D imaging. Week 16 is 4 weeks after the final treatment.
Time frame: Baseline (Week 0) and Week 16
Change From Baseline in Brow Height at Week 16
Mean change in brow height (mm) from baseline, measured by QuantifiCare 3D imaging. Week 16 is 4 weeks after the final treatment.
Time frame: Baseline (Week 0) and Week 16
Change From Baseline in Tear Trough Depth at Weeks 20 and 24
Mean change in tear trough depth (mm) from baseline, measured by QuantifiCare 3D imaging.
Time frame: Baseline (Week 0), Week 20, and Week 24
Change From Baseline in Brow Height at Weeks 20 and 24
Mean change in brow height (mm) from baseline, measured by QuantifiCare 3D imaging.
Time frame: Baseline (Week 0), Week 20, and Week 24
Change From Baseline in Periorbital Wrinkles, Pores, and Brown Spots
Mean change in periorbital wrinkles, pores, and brown spots from baseline, measured by the QuantifiCare 3D imaging Skincare Module.
Time frame: Baseline (Week 0), Weeks 16, 20, and 24
Investigator-Assessed Global Aesthetic Improvement Scale (GAIS)
Aesthetic improvement assessed by the investigator using the 5-point GAIS.
Time frame: Weeks 16, 20, and 24
FACE-Q Eye Module "Satisfaction With Eyes" Score
Subject-reported satisfaction with the appearance of the eyes, measured using the FACE-Q Eye Module "Satisfaction with Eyes" scale.
Time frame: Weeks 16, 20, and 24
Incidence and Severity of Adverse Events (AEs) and Adverse Device Effects (ADEs)
Number of participants with AEs and ADEs, and their severity, reported throughout the study period.
Time frame: Screening through Week 24
Plan to share: No — There is currently no plan to make individual participant data (IPD) available to other researchers.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jun 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
PharmaResearch Co.,Ltd